New York, NY -- (ReleaseWire) -- 01/07/2013 --AmarantusBioScience, Inc. (OTCQB: AMBS), a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented anti-apoptosis therapeutic protein MANF, announced that President & CEO Gerald Commissiong will make a corporate presentation at Biotech Showcase 2013 on Wednesday January 9, 2013 at 9:00am PST at the Parc 55 Wyndham Hotel in San Francisco, CA. “The presentations scheduled the week of the healthcare industry’s largest annual congregation of key decision makers in San Francisco will provide an ideal platform to introduce Amarantus to the broader investment community and biopharmaceutical executives,” said Gerald E. Commissiong, President & CEO.
Find out how this announcement could benefit AMBS by getting the free full report here: http://www.wallstreetreport.net/market-scan/?symbol=AMBS
Advanced Cell Technology, Inc., ("ACT" OTCQB: ACTC) is picking up speed on PR messages featuring health guru Doctor Oz. Dr. Oz only mentioned the potential of stem cell therapies in general and did not mention any specific companies. In the past, his TV endorsement has made the day for minor pharmaceutical companies by endorsing their food supplement products. Advanced Cell Technology, Inc., ("ACT" OTCBB: ACTC) is a biotechnology company that specializes in the development of cellular therapies for the treatment of diseases and conditions that impact tens of millions of people worldwide. The company applies stem cell-based technologies (both adult and human embryonic) and other proprietary methods in the field of regenerative medicine to bring patient-specific therapies from the lab bench to the bedside.
Find out where ACTC could be headed by getting the free full report here: http://www.wallstreetreport.net/market-scan/?symbol=ACTC
WallStreetReport.net issues momentum alerts on stocks that can provide gains to day traders. WallStreetReport.net provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. WallStreetReport.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.Through a vast network of IR professionals WallStreetReport.net is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the WallStreetReport.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Report believes traders should have a chance at successfully trading Penny Stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.WallStreetReport.net
Disclosure: WallStreetReport.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetreport.Net website, for complete risks and disclosures.
BlueLys, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.
WALL STREET REPORT